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Purpose: Filgrastim, a granulocyte-colony stimulating factor, is used to treat patients with 
neutropenia, including neutropenic fever. Leucostim® is a recombinant filgrastim product tested 
for biosimilarity with its reference product, Neupogen®. We conducted a comparative clinical 
trial of the 2 products.
Patients and methods: A randomized, open-label, 2-way crossover, single-dose Phase I 
study was conducted for 56 healthy subjects. After a 5 and 10 μg/kg single subcutaneous 
administration of test and reference product, pharmacokinetic and pharmacodynamic parameters 
(absolute neutrophil count and CD34+ cell count) were compared. During the study, safety tests 
and adverse event monitoring were performed.
Results: The test and the reference products had a comparable pharmacokinetic, pharmacody-
namic, and safety profile. In both 5 and 10 μg/kg dosing, the 90% CIs of the test to reference 
ratio for primary parameters (peak plasma concentration and area under the plasma concentration 
vs time curve from time 0 extrapolated to the infinite time for plasma filgrastim concentration; 
maximal effect and area under the time-effect curve from time 0 to time of the last quantifiable 
effect for absolute neutrophil count) were within the 0.8–1.25 range. In addition, safety profiles 
between the 2 products were similar without any serious adverse events.
Conclusion: This study has provided firm clinical evidence that the test filgrastim product is 
similar to its reference filgrastim product.
Keywords: bioequivalence, biosimilar, G-CSF, biologics
Introduction
Intensive chemotherapy in cancer patients can cause neutropenic fever and infection, 
which delays chemotherapy cycles and increases mortality and morbidity of chemo-
therapy-treated patients.1 Granulocyte-colony stimulating factors (G-CSFs), which 
stimulate and control the proliferation and differentiation of leukocytes, neutrophils, 
and macrophages, help prevent bone marrow suppression and reduce the incidence 
of neutropenic fever.2,3 In addition, use of G-CSFs on febrile neutropenia is related to 
reduced infection-related death and all-cause mortality.4,5 Thus, prophylactic use of 
G-CSFs in patients at high risk (20%) of fever and neutropenia is recommended.2
Neupogen® is the first commercial pharmaceutical analog of G-CSF from Amgen 
Inc. (Thousand Oaks, CA, USA), which was manufactured using recombinant 
Escherichia coli bacteria with human G-CSF gene. It has similarities to endogenous 
G-CSF in terms of structure (except for the addition of an N-terminal methionine), 
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efficacy, and safety profile. It has been a great success since 
its first approval in 1998 and is still among the top 15 best-
selling drugs of 2016.6
Several filgrastim products have been developed since 
the approval of the original product. In the European Union, 
starting from 2008, 9 filgrastim biosimilars were approved 
and 7 products are currently in use.7 In the USA, Sandoz Inc. 
(Princeton, NJ, USA) got approval of Zarxio®, which was 
the first biosimilar product passed through the US Food and 
Drug Administration (FDA) biosimilar approval pathway.8 
In 2017, it is still the only biosimilar filgrastim product 
available in USA.
In Korea, Dong-A ST (Seoul, Korea) developed a 
recombinant human G-CSF, Leucostim®. It is synthesized by 
recombinant protein expression in E. coli and is activated by 
a refolding process. In the biochemical testing, it has been 
shown that the biological efficacy was equivalent to the 
endogenous G-CSF. The formulation is identical to the origi-
nal product except addition of D-mannitol as an excipient.
It is essential to determine similarity between the bio-
similar and the reference product. Tests should be done 
with regard to physicochemical characteristics (structure), 
biological activity/potency (function), safety, and efficacy 
profiles.9,10 In the process of biosimilar development, clinical 
pharmacology plays a critical part as it provides evidence 
that there are no clinically meaningful differences in terms 
of pharmacokinetics (PKs) and pharmacodynamics (PDs).11 
To prove biosimilarity between the test filgrastim product and 
its reference filgrastim product, we conducted a comparative 
clinical trial of the 2 products.
Patients and methods
Study design
This study was conducted in accordance with the ethical 
principles of Good Clinical Practice and to the latest Declara-
tion of Helsinki amendment. It was reviewed and approved 
by Severance Hospital Institutional Review Board, and 
the study information was registered on ClinicalTrials.gov 
(NCT02725086). This was a randomized, open-label, 2-way 
crossover, single-dose study with a washout period of 28 days. 
There were 2 dosing parts (5 and 10 μg/kg) in this study, with 
2 sequences in them. In each sequence, 14 healthy subjects 
were assigned to either the test drug or the reference drug 
in a crossover manner. All the subjects received infor-
mation on the details of the study and gave written informed 
consent. According to sequence and period, subjects received 
either a subcutaneous injection of the test product or the 
reference product. The overall study scheme is shown in 
Figure 1. The primary objective was to compare PK param-
eters (peak plasma concentration [C
max
] and area under the 
time-concentration curve from time 0 to infinity [AUC
inf
]) 
and PD parameters (maximal effect [E
max
] and area under 
the time-effect curve from time 0 to 120 h [AUEC
0–120 h
] of 
absolute neutrophil count [ANC]) between the test product 
and the reference product.
Subjects
Healthy male subjects aged 19–45 years volunteered for this 
study. Body mass index of the subjects had to be 18.5 kg/m2 
or greater but 25.0 kg/m2, with a minimum weight of 60 kg. 
Subjects with histories of receiving recombinant G-CSF were 
excluded, and the ANC had to be between 2×103/μL and 7×103/μL. 
In the screening process, vital signs (blood pressure, pulse 
rate, and body temperature), laboratory analyses (hematology, 
blood chemistry, coagulation, urinalysis), 12-lead electrocar-
diogram (ECG), urine drug screening, and serology testing 
were performed. Fifty-six eligible subjects participated in the 
study. They had no clinically significant screening results and 
had no relevant medical or medication histories.
procedures
After providing written informed consent, the subjects attended 
an initial screening visit to undergo screening procedures 
between 2 and 28 days prior to the first dosing. On Day −1, 
eligible subjects were admitted to the clinical trials center 
at Severance Hospital and randomized. After an overnight 
5DQGRPL]DWLRQ 'RVLQJ 'RVLQJ )ROORZXSYLVLW
3.3'VDPSOLQJ6FUHHQLQJ
3HULRG 3HULRG'D\± ±     'D\±
3.3'VDPSOLQJ:DVKRXW
Figure 1 Schematic diagram of study design.
Abbreviation: pK/pD, pharmacokinetic/pharmacodynamic.
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fast, subjects were administered a single dose of filgrastim on 
the early morning of Day 1. Either the test or reference drug 
was administered by the pre-assigned sequence. Blood was 
drawn for PK and PD evaluation at prespecified time points. 
On Day 3, the subjects had 48-hour PK/PD samples drawn, 
underwent a repeated safety assessment, and were discharged 
from the site. PD sampling after discharge was performed via 
subsequent visits according to a predetermined time schedule. 
After a 28-day washout period, period 2 was conducted in a 
crossover manner. On Day 14±2 of period 2, subjects under-
went a follow-up visit for final safety assessments. During the 
hospital stay and at follow-up, adverse event (AE) monitor-
ing, concomitant medication recording, laboratory analyses 
(hematology, blood chemistry, coagulation, urinalysis), physi-
cal examination, vital signs (blood pressure, pulse rate, and 
body temperature), and 12-lead ECG were also performed. 
To examine drug immunogenicity, anti-filgrastim antibodies 
test was performed at each admission and follow-up.
From 2 days prior to the first study drug administration, 
the subjects were prohibited from consuming excessive 
alcohol (210 g/week) or caffeine. No alcohol, smoking, or 
xanthine beverage (coffee, coke, or tea) was allowed within 
2 days prior to admission of each period. Drugs including 
ethical/over-the-counter drugs, vitamins, oriental medicines, 
and functional foods were restricted. Subjects received stan-
dard meals during hospital stay, and food or drink brought 
from outside was not allowed.
Drug assay and cell counting
For PK sampling, 8 mL blood sample was collected into 
an EDTA Vacutainer® based on the PK sampling schedule: 
at pre-dose (0 hours), and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 
and 48 hours post-dose. Within 60 minutes of blood draw, 
the blood sample was centrifuged (1,800 g, 4°C, 8 minutes 
to separate the plasma) and stored at −70°C or below until 
analysis. Plasma filgrastim concentrations were measured 
using a solid phase enzyme-linked immunosorbent assay 
(Quantikine® Human G-CSF Immunoassay; R&D Systems, 
Inc., Minneapolis, MN, USA). The range of calibration curve 
was set at 0–625 pg/mL and the lower limit of quantification 
was 5.05 pg/mL. The curves were determined to be linear 
with all coefficient values over 0.99. The accuracy was within 
80%–120% and all quality control samples were within the 
pre-defined quality control range.
For analysis of ANC and CD34+ cell count, 3 mL of 
blood was collected into EDTA tubes. ANC sampling was 
performed at pre-dose (0 hours), and 2, 4, 8, 12, 16, 20, 24, 28, 
36, 48, 72, 96, and 120 hours post-dose; and CD34+ cell count 
sampling was performed at pre-dose (0 hours), and 24, 48, 
72, 96, 120, 168, 240, and 312 hours post-dose. PD samples 
were stored at ambient temperature prior to analysis. The 
ANC was measured using XN-series (Sysmex, Kobe, Japan). 
The CD34+ cell count was measured using a flow cytometer 
(BD™ FACSVerse™; BD Bioscience, San Jose, CA, USA) 
and enumeration kits for CD34+ cell (BD Stem Cell Enumera-
tion Kit and BD Stem Cell Control Kit; BD Bioscience).
pK and pD analyses
The plasma concentration data of filgrastim, ANC, and 
CD34+ cell count was analyzed using non-compartmental 
analysis engine of Phoenix® WinNonlin® (version 6.4; Phar-
sight, CA, USA). The C
max
, E
max
, and time to C
max
 or E
max
 (t
max
) 
were directly obtained from the raw data. The terminal slope 
of plasma filgrastim (λ
z
) was calculated using the automated 
method, which is based on the maximum best-adjusted 
coefficient of determination (R2) with at least 3 points. The 
terminal half-life of plasma filgrastim (t
1/2
) was calculated as 
follows: t
1/2
 = ln2/λ
z
. The area under the time-concentration 
curve (AUC
0–last
: from time 0 to time of the last quantifiable 
concentration; AUC
0–∞: from time 0 extrapolated to infinity) 
and the area under the time-effect curve from time 0 to time 
of the last quantifiable effect (AUEC
0–last
) were calculated 
using the linear trapezoidal method.
Statistical analysis of pK and pD
The sample size was calculated by examining other products 
of rhG-CSF. From reviews of recently developed rhG-CSF 
products,12–14 the intra-subject coefficients of variations (CV
w
) 
of AUC
inf
 and C
max
 of filgrastim were 15.6%–20.29% and 
13.64%–23.94%, respectively. Based on the data, using the 
greatest CV
w
, 23.94%, at a significance level of 0.05 with 
80% power, the required sample size was calculated to be 
11 subjects/group using a modified Hauschke’s equation.15 
Using an assumption of a 20% dropout rate, the required 
sample size was 28 subjects/dosing part, to give 56 subjects 
in total.
The PK and PD population were defined as those who 
received the scheduled doses and PK and PD sampling 
schedules, respectively, according to the protocol. Descrip-
tive statistics for PK and PD parameters were provided with 
the ranges of SDs except t
max
 (presented as median [min, 
max]). The primary PK (C
max
 and AUC
0–∞) and PD (Emax and 
AUEC
0–last
) parameters were log-transformed and determined 
whether the 90% CI of the test to reference ratio fell within the 
range of 0.8–1.25. For the test, a linear mixed effect analysis 
was performed using the bioequivalence engine in Phoenix 
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WinNonlin (version 6.4). The model included sequence, 
subjects nested in sequences, period, and treatment.
Results
Fifty-six subjects were enrolled, and all subjects were 
administered the study drug at least once. Among them, 
54 and 53 subjects who underwent the study schedule and 
had complete PK and PD study results were included in the 
PK analysis and PD analysis, respectively.
pKs
The plasma filgrastim concentrations, ANC, and CD34+ cell 
counts over time are shown in Figure 2 and PK parameters are 
provided in Table 1. For both the test and reference products, 
plasma concentrations of filgrastim started to increase from 
the time of subcutaneous administration and reached C
max
 
at 6 hours in both 5 and 10 μg/kg dose groups. After t
max
, 
the concentrations decreased and reached nearly zero at 
36 hours, with half-lives about 7 hours. In the PK analysis, 
primary assessment parameters (90% CIs of the ratios 
between the log-transformed C
max
 and AUC
0–∞ of the test and 
reference products) were within 0.8–1.25 (Table 1).
pDs
At the dose of 5 μg/kg, ANC showed median t
max
 values of 
18 and 12 hours for the test and reference drug, respectively; 
while the median t
max
 values were identical at 24 hours at 
10 μg/kg dose. For doses of 5 and 10 μg/kg, CD34+ cell 
counts reached t
max
 at 96 and 72 hours, respectively, regard-
less of study drug. The primary assessment parameters for 
PD, E
max
 and AUEC
0–last
 for ANC, and the 90% CIs of the 
ratios of the log-transformed values of the test to reference 
products were within 0.8–1.25 (Table 1).
Safety
During the study, 29 subjects reported 60 AEs related to 
the study drug (Table 2). Most AEs were related to pain 
and blood disorders, including back pain, neutropenia, and 
leukopenia. All AEs were mild in severity and none serious. 
At post-study period, subjects with AEs were followed up 
and all contactable subjects were confirmed to have fully 
recovered. In addition, no subjects in this study devel-
oped anti-filgrastim antibodies during hospital stay and at 
follow-up.
Discussion
The purpose of this study was to compare PK, PD, and safety 
between a biosimilar filgrastim product and the reference 
product following a single subcutaneous injection. According 
to the FDA biosimilar guidance, the dose selected should be 
one most likely to provide clinically meaningful and inter-
pretable data.11 Because the development plan aimed to use 
Figure 2 arithmetic mean ± SD values for pharmacokinetics and pharmacodynamics of filgrastim following single administration of Neupogen or Leucostim.
Notes: Plasma filgrastim concentration (A), absolute neutrophil count (B), and CD34+ cell count (C). Lower limit of quantification for plasma filgrastim: 5.05 pg/mL.
20
15
10
5
0
0
Time after administration (h)
C
D
34
+  c
el
l c
ou
nt
 (/
µL
)
2882401921449648
60
50
40
30
20
10
0
0 12 24
Time after administration (h)
Pl
as
m
a 
fil
gr
as
tim
co
nc
en
tr
at
io
n 
(n
g/
m
L)
36 48
30
25
20
15
10
5
0
0
Time after administration (h)
A
bs
ol
ut
e 
ne
ut
ro
ph
il
co
un
t (
×1
09
/L
)
24 48 72 96 120
Leucostim® 5 µg/kg Neupogen® 5 µg/kg Leucostim® 10 µg/kg Neupogen® 10 µg/kg
A B
C
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
13
4.
20
7.
84
 o
n 
24
-J
un
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2018:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2385
Comparison between biosimilar filgrastim and its reference product
the test product for the indications of the reference product 
at doses of 5 and 10 μg/kg, this study was conducted with 
the 2 dosing parts (5 and 10 μg/kg). The sampling schedule 
were set based on PK data of the reference product14,16–18 and 
the in-house test product data. The sampling intervals were 
appropriately set to observe the profiles of PK and PD, and 
the last time points were set sufficiently long for all measure-
ments to return to the baselines.
To prove biosimilarity between the 2 filgrastim products, 
ANC and CD34+ cell counts were evaluated as well as plasma 
drug concentration measurements.14,19 On PK evaluation, the 
90% CIs of the test to reference ratios for the primary assess-
ment parameters (C
max
 and AUC
0–∞) were within 80%–125%, 
suggesting that a sufficient similarity exists between the 
2 products. In PD evaluation, E
max
 and AUEC
0–last
 for ANC 
were primary assessment parameters, and the 90% CIs were 
Table 1 pharmacokinetic and pharmacodynamic parameters for administration of neupogen® or leucostim®
Parameter 5 μg/kg 10 μg/kg
Leucostim 
(Na=27)
Neupogen 
(Na=27)
Ratio (90% CI) Leucostim 
(N=27)
Neupogen  
(N=27)
Ratio (90% CI)
Pharmacokinetics
Cmax (ng/mL) 33.75 (10.00) 35.83 (9.35) 0.94 (0.82–1.07) 51.37 (15.77) 55.14 (8.30) 0.90 (0.81–0.99)
aUC0–48 h (h⋅ng/ml) 302.6 (106.7) 315.1 (94.0) 570.7 (133.1) 621.3 (133.3)
aUC0–∞ (h⋅ng/ml) 304.4 (106.2) 316.5 (93.8) 0.94 (0.84–1.06) 572.3 (133.0) 622.6 (133.4) 0.92 (0.82–1.03)
tmax (h) 6.00 (4.00–12.00) 6.00 (4.00–8.00) 6.00 (4.00–12.00) 6.00 (4.00–8.00)
t1/2 (h) 7.37 (3.42) 6.95 (3.53) 4.95 (3.64) 4.56 (0.94)
Pharmacodynamics
anC
Emax (×109/l) 23.30 (4.58) 23.25 (4.46) 1.00 (0.97–1.04) 25.24 (4.74) 25.07 (4.67) 1.00 (0.96–1.05)
aUeC0–120 h (×109 h/l) 1,254.1 (217.9) 1,217.0 (204.5) 1.03 (1.01–1.06) 1,544.0 (282.5) 1,497.8 (267.2) 1.03 (1.00–1.06)
tmax (h) 18.00 (12.00–28.00) 12.00 (12.00–24.00) 24.00 (20.00–28.00) 24.00 (12.00–28.00)
CD34+ cell count
Emax (/μl) 5.44 (2.51) 5.40 (3.87) 1.13 (0.96–1.32) 10.44 (7.53) 9.92 (6.83) 1.03 (0.92–1.15)
aUeC0–312 h (h/μl) 813.4 (313.0) 826.5 (435.4) 1.06 (0.97–1.16) 1,178.1 (773.1) 1,084.1 (652.7) 1.05 (0.98–1.13)
tmax (h) 96.00 (24.00–240.00) 96.00 (48.00–120.67) 72.00 (48.00–96.00) 72.00 (48.00–119.53)
Notes: Parameters are presented as the arithmetic mean (SD), except for tmax (presented as median [min, max]). 
aThe number of subjects in the pharmacodynamic population 
(5 μg/kg) was 26. The 90% CI of the ratio of logarithmically transformed parameters was calculated as with Leucostim vs Neupogen.
Abbreviations: aUC0–48 h, area under the plasma concentration vs time curve from time 0 to time of the last measurable concentration (48 h); AUC0–∞, area under the 
plasma concentration vs time curve from time 0 extrapolated to the infinite time; AUEC0–12h, area under the time-effect curve from time 0 to 120 h; aUeC0–312h, area under 
the time-effect curve from time 0 to 312 h; CI, confidence interval; Cmax, maximum plasma concentration; Emax, maximum effect; GMr, geometric least squares mean ratio; 
tmax, time of maximum drug concentration or effect; t1/2, terminal half-life.
Table 2 Summary of adverse events by system organ class
System organ class and preferred 
terma
Number of subjects with adverse events (%)
5 μg/kg 10 μg/kg
Neupogen 
(N=28)
Leucostim 
(N=27)
Neupogen 
(N=27)
Leucostim 
(N=28)
Subjects with any adverse event 9 (32.1) 10 (37.0) 17 (63.0) 14 (50.0)
Musculoskeletal and connective tissue 
disorders
3 (10.7) 4 (14.8) 6 (22.2) 9 (32.1)
Back pain 1 (3.6) 3 (11.1) 5 (18.5) 9 (32.1)
Bone pain na 1 (3.7) 1 (3.7) na
arthralgia 1 (3.6) na na na
Myalgia 1 (3.6) na na na
pain in extremity na 1 (3.7) na na
Blood and lymphatic system disorders 4 (14.3) 5 (18.5) 4 (14.8) 3 (10.7)
neutropenia 4 (14.3) 3 (11.1) 4 (14.8) 3 (10.7)
leukopenia 1 (3.6) 2 (7.4) 3 (11.1) na
leukocytosis na na 1 (3.7) na
investigations 2 (7.1) 1 (3.7) 4 (14.8) 2 (7.1)
Blood creatine phosphokinase increased 2 (7.1) na 4 (14.8) 1 (3.6)
alanine aminotransferase increased na 1 (3.7) na na
C-reactive protein increased 1 (3.6) na na na
Gamma-glutamyltransferase increased na na na 1 (3.6)
Note: aSystem organ class and preferred term according to MedDra® (version 18.1).
Abbreviation: na, not applicable.
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also within 0.8–1.25 range. Although one of the secondary 
assessment parameters of PD, the 90% CI for E
max
 of CD34+ 
cell counts, at 5 μg/kg dose fell outside 0.8–1.25 range, the 
other CIs were within the ranges that satisfy biosimilarity. 
The overall effect-time profiles between the 2 products could 
be considered comparable.
Regarding the safety, occurrence of AEs for the 2 products 
appeared to be similar (Table 2). The most frequent AE was 
pain, which was consistent with the pivotal clinical trial that 
showed around 20% of patients with mild-to-moderate bone 
pain.20 Regardless of product, pain seems to occur depending 
on dose. Almost double the subjects suffered from pain when 
the dose doubled. In other biosimilar filgrastim products, pain-
related disorders were also the major AEs and, generally, the 
safety profile was comparable.14,16,17,21–25 Disorders related to 
laboratory results such as neutropenia or “blood creatinine 
phosphokinase increased” were only observed in this study. 
Nevertheless, it is unlikely that the AEs are product-specific, 
and it is possibly attributed to the AE collection method because 
the AEs were observed both in the test and the reference.
Conclusion
A clinical study with a filgrastim biosimilar product, and its 
reference product was conducted to evaluate biosimilarity 
between the 2 products in terms of PKs, PDs, and safety. The 
analyses of primary PK and PD parameters showed sufficient 
biosimilarity between the 2 products, and the safety profiles 
were comparable.
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